Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue of Rs 3,623 crore. This represented a flat year-on-year change, with operational revenue at Rs 3,590 crore, showing a 4% increase compared to the previous year. The company emphasized an 8% growth in operating revenue when adjusted […]
In a strategic move to tackle the growing diabetes crisis in the Middle East, Biocon Limited has announced a partnership with Tabuk Pharmaceutical Manufacturing Company. This alliance aims to commercialize Biocon’s Glucagon-like peptide-1 (GLP-1) products across the Middle East, specifically focusing on Saudi Arabia and neighboring regions. GLP-1 products, which are increasingly recognized for their […]
Biocon Limited (BSE code: 532523, NSE: BIOCON), a leader in global biopharmaceutical innovations, has announced a pivotal licensing and supply agreement with Brazil’s Biomm S.A., a specialty pharmaceutical company, to commercialize Semaglutide, a drug aimed at enhancing glycemic control in adults with type-2 diabetes. This exclusive partnership allows Biocon to handle the development, manufacturing, and […]